Clinical trials: Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11

Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

• Completed
• Age: 18 to 64 years
• Phase 1
• Injection or infusion

This phase I trial studies the side effects and best dose of lenalidomide when given together with cytarabine and idarubicin in treating patients with acute myeloid leukemia.

Conditions

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1

Trial name

NCT01132586

Testing

Lenalidomide, Cytarabine, Idarubicin

Where

United States

Volunteers

61 people

Sponsor

National Cancer Institute (NCI)